Abstract
In the last few years, several studies emerged for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SSc). Some of the studied drugs showed efficacy compared to placebo or to a control group. Since early 2020, nintedanib has been approved for the treatment of SSc-ILD. Although several drugs are used to treat SSc-LD, it is now the first approved drug for SSc-ILD. Here, we aim to provide an overview about our current therapy algorithm and strategy as well as our interpretation of study results as an experienced SSc-ILD center.
| Translated title of the contribution | How do I treat interstitial lung disease in systemic sclerosis? |
|---|---|
| Original language | German |
| Journal | Zeitschrift fur Rheumatologie |
| Volume | 80 |
| Issue number | 1 |
| Pages (from-to) | 69-72 |
| Number of pages | 4 |
| ISSN | 0340-1855 |
| DOIs | |
| Publication status | Published - 02.2021 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
- Centers: Center for Rare Diseases (ZSE)
DFG Research Classification Scheme
- 204-05 Immunology
- 205-18 Rheumatology
